Portola Pharmaceuticals, Inc. announced the presentation of new data demonstrating that using Andexxa [coagulation factor Xa (recombinant), inactivated-zhzo] to treat patients with intracranial hemorrhage (ICH) associated with the oral Factor Xa inhibitors apixaban or rivaroxaban is projected to provide a net reduction in costs to an acute care hospital. The data was presented by John Fanikos, B.Pharm., M.B.A., executive director of pharmacy services at Brigham and Women's Hospital, Boston, in a poster session at the Emergencies in Medicine Meeting, which is taking place March 1-6 in Park City, Utah. The analysis compared a clinical scenario with Andexxa the first and only antidote approved by the U.S. Food and Drug Administration (FDA) for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding to one without it where patients were given 4-Factor Prothrombin Complex Concentrate (4F-PCC), which is only approved for the reversal of warfarin and has no impact on anti-Factor Xa levels. Key findings from this analysis related to the net cost reduction Andexxa can provide for the treatment of ICH associated with oral Factor Xa inhibitors include: The total cost per hospitalization, considering new technology add-on payment (NTAP) reimbursement for eligible claims, was $49,291 for patients treated with Andexxa and $54,699 for patients treated with 4F-PCC demonstrating a cost reduction of $5,408 with the use of Andexxa. As a result, the analysis projected a potential total annual cost reduction of $259,608 for a hospital treating 48 of these patients per year with Andexxa in place of 4F-PCC. Andexxa generated reductions in all cost components " intubation, intensive care unit (ICU) and surgery costs except drug costs, though drug costs were offset by the NTAP reimbursement. The projected net cost reduction related to the use of Andexxa over three years totaled $392,652, assuming a proportional share of 4F-PCC use (based initially on current utilization in clinical practice). Based on previously published clinical evidence, the model assumes a lower risk of hematoma expansion and surgery in patients treated with Andexxa compared to patients treated with 4F-PCC. The model also considered the NTAP reimbursement available for Andexxa, a CMS designation enabling hospitals to recoup up to 65% of the cost of the drug when applied successfully.